Article: NEW NASAL SPRAY TREATMENT FOR POSTMENOPAUSAL OSTEOPOROSIS

EAST HANOVER, N.J., Aug. 18 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation announced today that it has received clearance to market MIACALCIN(R) Nasal Spray (calcitonin-salmon) for the treatment of postmenopausal osteoporosis. Widening the therapeutic options for a crippling and sometimes life-threatening bone disease affecting more than 20 million American women, MIACALCIN Nasal Spray offers a new approach in the delivery of osteoporosis therapy. Clinical studies with MIACALCIN Nasal Spray have shown significant increases in spinal bone mineral density in women more than five years after menopause.

"While estrogens are considered first line therapy for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!